Does the liver synthesize albumin, and can metabolic dysfunction or inflammation reduce it?

The liver is the sole site of circulating albumin synthesis, maintaining systemic homeostasis through a high baseline production rate. However, both metabolic dysfunction and systemic inflammation directly impair this vital biosynthetic pathway through distinct molecular mechanisms.

Baseline physiological synthesis

• Exclusive hepatic production: Hepatocytes transcribe and translate albumin on the rough endoplasmic reticulum, secreting approximately 10 to 15 grams per day (about 150 mg/kg/day in a standard adult) to maintain intravascular oncotic pressure and transport systemic molecules.

Mechanistic drivers of suppression

• Metabolic ER stress: In metabolic dysfunction-associated steatotic liver disease (MASLD), chronic lipid overload induces endoplasmic reticulum (ER) stress. This activates the PERK-eIF2α pathway, triggering global translational attenuation and secretory pathway failure. This is further compounded by mitochondrial oxidative stress, which depletes the cellular energy required for high-rate biosynthesis.
• Inflammatory transcriptional reprogramming: Albumin is a negative acute-phase protein, meaning its synthesis is actively suppressed during inflammatory states. Interleukin-6 (IL-6) acts via the JAK/STAT3 pathway to redirect hepatocyte resources toward positive acute-phase reactants (such as CRP and fibrinogen), while TNF-α signals through NF-κB to directly inhibit albumin transcription and induce mitochondrial dysfunction.

Bottom line

• While the liver normally synthesizes 10 to 15 grams of albumin daily, this output is directly and synergistically constrained by metabolic dysfunction—via ER stress-induced translational arrest—and inflammation—via cytokine-mediated transcriptional reprogramming.